Patrick Forde
Trinity St James Cancer Institute, Dublin, Ireland · Johns Hopkins University · John Hopkins
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patrick Forde as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06931717 · A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyETOP IBCSG Partners Foundation · recruiting · Non-Small Cell Lung Cancer · study chair
- Ph3NCT04334759 · DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaPrECOG, LLC. · completed · Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma · study chair
- Ph2NCT03237377 · Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT02899195 · Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable MesotheliomaPrECOG, LLC. · completed · Mesothelioma, Pleural Mesothelioma · study chair
- Ph2NCT02864316 · Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation ExposureSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Solid Tumors Induced by Prior Radiation Exposure · principal investigator
- Ph2NCT02259621 · Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med · 20222,541 citationsRCR 184.1
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med · 20181,689 citationsRCR 52.2
- 499 citationsRCR 13.9
- Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.Clin Cancer Res · 2021320 citationsRCR 15.3
- PD-1 Blockade in Anaplastic Thyroid Carcinoma.J Clin Oncol · 2020278 citationsRCR 12.2
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.J Thorac Cardiovasc Surg · 2019267 citationsRCR 9.0
- 245 citationsRCR 50.5
- 151 citationsRCR 4.6
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer Discov · 2023131 citationsRCR 8.5
- Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.Nat Med · 2024121 citationsRCR 12.1